APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA-based Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Industry Research

RNA-based Biopharmaceuticals Industry Research Report 2026

20 December 2025134 pages

Choose your research edition.

Industry ResearchRNA-based Biopharmaceuticals Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-based Biopharmaceuticals Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal RNA-based Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-based Biopharmaceuticals Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-based Biopharmaceuticals Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global RNA-based Biopharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for RNA-based Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for RNA-based Biopharmaceuticals is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for RNA-based Biopharmaceuticals is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of RNA-based Biopharmaceuticals include Roche, Pfizer, Tekmira, Silenseed, Silence Therapeutics, Senesco, Sanofi-Aventis, RXi and Quark, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global RNA-based Biopharmaceuticals market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

RNA-based Biopharmaceuticals Market by Company

Roche

Pfizer

Tekmira

Silenseed

Silence Therapeutics

Senesco

Sanofi-Aventis

RXi

Quark

Gradalis

Dicerna

Calimmune Inc

Benitec Biopharma

Arrowhead Pharmaceuticals

Alnylam Pharmaceuticals

Abbott Laboratories

RNA-based Biopharmaceuticals Segment by Type

Therapeutics

Vaccines

RNA-based Biopharmaceuticals Segment by Application

Cancer

Tuberculosis

Diabetes

Cardiovascular Diseases

Others

RNA-based Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-based Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-based Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-based Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of RNA-based Biopharmaceuticals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of RNA-based Biopharmaceuticals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of RNA-based Biopharmaceuticals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global RNA-based Biopharmaceuticals Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global RNA-based Biopharmaceuticals Sales (k units) of Manufacturers (2021-2026) Table 7. Global RNA-based Biopharmaceuticals Sales Market Share by Manufacturers (2021-2026) Table 8. Global RNA-based Biopharmaceuticals Revenue of Manufacturers (2021-2026) Table 9. Global RNA-based Biopharmaceuticals Revenue Share by Manufacturers (2021-2026) Table 10. Global Market RNA-based Biopharmaceuticals Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global RNA-based Biopharmaceuticals Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of RNA-based Biopharmaceuticals, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of RNA-based Biopharmaceuticals, Product Type & Application Table 14. Global RNA-based Biopharmaceuticals Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global RNA-based Biopharmaceuticals by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Roche Company Information Table 19. Roche Business Overview Table 20. Roche RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Roche RNA-based Biopharmaceuticals Product Portfolio Table 22. Roche Recent Developments Table 23. Pfizer Company Information Table 24. Pfizer Business Overview Table 25. Pfizer RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Pfizer RNA-based Biopharmaceuticals Product Portfolio Table 27. Pfizer Recent Developments Table 28. Tekmira Company Information Table 29. Tekmira Business Overview Table 30. Tekmira RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Tekmira RNA-based Biopharmaceuticals Product Portfolio Table 32. Tekmira Recent Developments Table 33. Silenseed Company Information Table 34. Silenseed Business Overview Table 35. Silenseed RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Silenseed RNA-based Biopharmaceuticals Product Portfolio Table 37. Silenseed Recent Developments Table 38. Silence Therapeutics Company Information Table 39. Silence Therapeutics Business Overview Table 40. Silence Therapeutics RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio Table 42. Silence Therapeutics Recent Developments Table 43. Senesco Company Information Table 44. Senesco Business Overview Table 45. Senesco RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Senesco RNA-based Biopharmaceuticals Product Portfolio Table 47. Senesco Recent Developments Table 48. Sanofi-Aventis Company Information Table 49. Sanofi-Aventis Business Overview Table 50. Sanofi-Aventis RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio Table 52. Sanofi-Aventis Recent Developments Table 53. RXi Company Information Table 54. RXi Business Overview Table 55. RXi RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. RXi RNA-based Biopharmaceuticals Product Portfolio Table 57. RXi Recent Developments Table 58. Quark Company Information Table 59. Quark Business Overview Table 60. Quark RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Quark RNA-based Biopharmaceuticals Product Portfolio Table 62. Quark Recent Developments Table 63. Gradalis Company Information Table 64. Gradalis Business Overview Table 65. Gradalis RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Gradalis RNA-based Biopharmaceuticals Product Portfolio Table 67. Gradalis Recent Developments Table 68. Dicerna Company Information Table 69. Dicerna Business Overview Table 70. Dicerna RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Dicerna RNA-based Biopharmaceuticals Product Portfolio Table 72. Dicerna Recent Developments Table 73. Calimmune Inc Company Information Table 74. Calimmune Inc Business Overview Table 75. Calimmune Inc RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio Table 77. Calimmune Inc Recent Developments Table 78. Benitec Biopharma Company Information Table 79. Benitec Biopharma Business Overview Table 80. Benitec Biopharma RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio Table 82. Benitec Biopharma Recent Developments Table 83. Arrowhead Pharmaceuticals Company Information Table 84. Arrowhead Pharmaceuticals Business Overview Table 85. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio Table 87. Arrowhead Pharmaceuticals Recent Developments Table 88. Alnylam Pharmaceuticals Company Information Table 89. Alnylam Pharmaceuticals Business Overview Table 90. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio Table 92. Alnylam Pharmaceuticals Recent Developments Table 93. Abbott Laboratories Company Information Table 94. Abbott Laboratories Business Overview Table 95. Abbott Laboratories RNA-based Biopharmaceuticals Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio Table 97. Abbott Laboratories Recent Developments Table 98. Global RNA-based Biopharmaceuticals Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global RNA-based Biopharmaceuticals Sales by Region (2021-2026) & (k units) Table 100. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2021-2026) Table 101. Global RNA-based Biopharmaceuticals Sales by Region (2027-2032) & (k units) Table 102. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2027-2032) Table 103. Global RNA-based Biopharmaceuticals Revenue by Region (2021-2026) & (US$ Million) Table 104. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2021-2026) Table 105. Global RNA-based Biopharmaceuticals Revenue by Region (2027-2032) & (US$ Million) Table 106. Global RNA-based Biopharmaceuticals Revenue Market Share by Region (2027-2032) Table 107. North America RNA-based Biopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 109. North America RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 110. North America RNA-based Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 111. North America RNA-based Biopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe RNA-based Biopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 114. Europe RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 115. Europe RNA-based Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe RNA-based Biopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific RNA-based Biopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 119. Asia Pacific RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 120. Asia Pacific RNA-based Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific RNA-based Biopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 122. South America RNA-based Biopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 124. South America RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 125. South America RNA-based Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 126. South America RNA-based Biopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa RNA-based Biopharmaceuticals Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 129. Middle East and Africa RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 130. Middle East and Africa RNA-based Biopharmaceuticals Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa RNA-based Biopharmaceuticals Revenue by Country (2027-2032) & (US$ Million) Table 132. Global RNA-based Biopharmaceuticals Sales by Type (2021-2026) & (k units) Table 133. Global RNA-based Biopharmaceuticals Sales by Type (2027-2032) & (k units) Table 134. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2026) Table 135. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2027-2032) Table 136. Global RNA-based Biopharmaceuticals Revenue by Type (2021-2026) & (US$ Million) Table 137. Global RNA-based Biopharmaceuticals Revenue by Type (2027-2032) & (US$ Million) Table 138. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2026) Table 139. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2027-2032) Table 140. Global RNA-based Biopharmaceuticals Price by Type (2021-2026) & (US$/unit) Table 141. Global RNA-based Biopharmaceuticals Price by Type (2027-2032) & (US$/unit) Table 142. Global RNA-based Biopharmaceuticals Sales by Application (2021-2026) & (k units) Table 143. Global RNA-based Biopharmaceuticals Sales by Application (2027-2032) & (k units) Table 144. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2026) Table 145. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2027-2032) Table 146. Global RNA-based Biopharmaceuticals Revenue by Application (2021-2026) & (US$ Million) Table 147. Global RNA-based Biopharmaceuticals Revenue by Application (2027-2032) & (US$ Million) Table 148. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2026) Table 149. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2027-2032) Table 150. Global RNA-based Biopharmaceuticals Price by Application (2021-2026) & (US$/unit) Table 151. Global RNA-based Biopharmaceuticals Price by Application (2027-2032) & (US$/unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. RNA-based Biopharmaceuticals Distributors List Table 155. RNA-based Biopharmaceuticals Customers List Table 156. RNA-based Biopharmaceuticals Industry Trends Table 157. RNA-based Biopharmaceuticals Industry Drivers Table 158. RNA-based Biopharmaceuticals Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. RNA-based Biopharmaceuticals Product Image Figure 5. Global RNA-based Biopharmaceuticals Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global RNA-based Biopharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 7. Global RNA-based Biopharmaceuticals Sales (2021-2032) & (k units) Figure 8. Global RNA-based Biopharmaceuticals Average Price (US$/unit) & (2021-2032) Figure 9. Therapeutics Product Image Figure 10. Vaccines Product Image Figure 11. Cancer Product Image Figure 12. Tuberculosis Product Image Figure 13. Diabetes Product Image Figure 14. Cardiovascular Diseases Product Image Figure 15. Others Product Image Figure 16. Global RNA-based Biopharmaceuticals Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of RNA-based Biopharmaceuticals, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 RNA-based Biopharmaceuticals Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global RNA-based Biopharmaceuticals Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global RNA-based Biopharmaceuticals Sales by Region in 2025 Figure 22. Global RNA-based Biopharmaceuticals Revenue by Region in 2025 Figure 23. North America RNA-based Biopharmaceuticals Market Size by Country in 2025 Figure 24. North America RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 25. North America RNA-based Biopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 26. United States RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe RNA-based Biopharmaceuticals Market Size by Country in 2025 Figure 30. Europe RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 31. Europe RNA-based Biopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 32. Germany RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific RNA-based Biopharmaceuticals Market Size by Country in 2025 Figure 43. Asia Pacific RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific RNA-based Biopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 45. China RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America RNA-based Biopharmaceuticals Market Size by Country in 2025 Figure 54. South America RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 55. South America RNA-based Biopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 56. Brazil RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa RNA-based Biopharmaceuticals Market Size by Country in 2025 Figure 60. Middle East and Africa RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa RNA-based Biopharmaceuticals Revenue Market Share by Country (2021-2032) Figure 62. Egypt RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries RNA-based Biopharmaceuticals Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2032) Figure 68. Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2032) Figure 69. Global RNA-based Biopharmaceuticals Price (US$/unit) by Type (2021-2032) Figure 70. Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2032) Figure 71. Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2032) Figure 72. Global RNA-based Biopharmaceuticals Price (US$/unit) by Application (2021-2032) Figure 73. RNA-based Biopharmaceuticals Value Chain Figure 74. RNA-based Biopharmaceuticals Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. RNA-based Biopharmaceuticals Industry Opportunities and Challenges

Scope & coverage.

Types
  • Therapeutics
  • Vaccines
Applications
  • Cancer
  • Tuberculosis
  • Diabetes
  • Cardiovascular Diseases
  • Others
Companies covered
  • Roche
  • Pfizer
  • Tekmira
  • Silenseed
  • Silence Therapeutics
  • Senesco
  • Sanofi-Aventis
  • RXi
  • Quark
  • Gradalis
  • Dicerna
  • Calimmune Inc
  • Benitec Biopharma
  • Arrowhead Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global RNA-based Biopharmaceuticals Market Size (2021-2032)
  4. 2.2.2 Global RNA-based Biopharmaceuticals Sales (2021-2032)
  5. 2.2.3 Global RNA-based Biopharmaceuticals Market Average Price (2021-2032)
  6. 2.3 RNA-based Biopharmaceuticals by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Therapeutics
  9. 2.3.3 Vaccines
  10. 2.4 RNA-based Biopharmaceuticals by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Cancer
  13. 2.4.3 Tuberculosis
  14. 2.4.4 Diabetes
  15. 2.4.5 Cardiovascular Diseases
  16. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global RNA-based Biopharmaceuticals Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global RNA-based Biopharmaceuticals Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global RNA-based Biopharmaceuticals Revenue of Manufacturers (2021-2026)
  4. 3.4 Global RNA-based Biopharmaceuticals Average Price by Manufacturers (2021-2026)
  5. 3.5 Global RNA-based Biopharmaceuticals Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of RNA-based Biopharmaceuticals, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of RNA-based Biopharmaceuticals, Product Type & Application
  8. 3.8 Global Manufacturers of RNA-based Biopharmaceuticals, Established Date
  9. 3.9 Global RNA-based Biopharmaceuticals Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Roche
  2. 4.1.1 Roche Company Information
  3. 4.1.2 Roche Business Overview
  4. 4.1.3 Roche RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Roche RNA-based Biopharmaceuticals Product Portfolio
  6. 4.1.5 Roche Recent Developments
  7. 4.2 Pfizer
  8. 4.2.1 Pfizer Company Information
  9. 4.2.2 Pfizer Business Overview
  10. 4.2.3 Pfizer RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pfizer RNA-based Biopharmaceuticals Product Portfolio
  12. 4.2.5 Pfizer Recent Developments
  13. 4.3 Tekmira
  14. 4.3.1 Tekmira Company Information
  15. 4.3.2 Tekmira Business Overview
  16. 4.3.3 Tekmira RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Tekmira RNA-based Biopharmaceuticals Product Portfolio
  18. 4.3.5 Tekmira Recent Developments
  19. 4.4 Silenseed
  20. 4.4.1 Silenseed Company Information
  21. 4.4.2 Silenseed Business Overview
  22. 4.4.3 Silenseed RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Silenseed RNA-based Biopharmaceuticals Product Portfolio
  24. 4.4.5 Silenseed Recent Developments
  25. 4.5 Silence Therapeutics
  26. 4.5.1 Silence Therapeutics Company Information
  27. 4.5.2 Silence Therapeutics Business Overview
  28. 4.5.3 Silence Therapeutics RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio
  30. 4.5.5 Silence Therapeutics Recent Developments
  31. 4.6 Senesco
  32. 4.6.1 Senesco Company Information
  33. 4.6.2 Senesco Business Overview
  34. 4.6.3 Senesco RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Senesco RNA-based Biopharmaceuticals Product Portfolio
  36. 4.6.5 Senesco Recent Developments
  37. 4.7 Sanofi-Aventis
  38. 4.7.1 Sanofi-Aventis Company Information
  39. 4.7.2 Sanofi-Aventis Business Overview
  40. 4.7.3 Sanofi-Aventis RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio
  42. 4.7.5 Sanofi-Aventis Recent Developments
  43. 4.8 RXi
  44. 4.8.1 RXi Company Information
  45. 4.8.2 RXi Business Overview
  46. 4.8.3 RXi RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 RXi RNA-based Biopharmaceuticals Product Portfolio
  48. 4.8.5 RXi Recent Developments
  49. 4.9 Quark
  50. 4.9.1 Quark Company Information
  51. 4.9.2 Quark Business Overview
  52. 4.9.3 Quark RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Quark RNA-based Biopharmaceuticals Product Portfolio
  54. 4.9.5 Quark Recent Developments
  55. 4.10 Gradalis
  56. 4.10.1 Gradalis Company Information
  57. 4.10.2 Gradalis Business Overview
  58. 4.10.3 Gradalis RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Gradalis RNA-based Biopharmaceuticals Product Portfolio
  60. 4.10.5 Gradalis Recent Developments
  61. 4.11 Dicerna
  62. 4.11.1 Dicerna Company Information
  63. 4.11.2 Dicerna Business Overview
  64. 4.11.3 Dicerna RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Dicerna RNA-based Biopharmaceuticals Product Portfolio
  66. 4.11.5 Dicerna Recent Developments
  67. 4.12 Calimmune Inc
  68. 4.12.1 Calimmune Inc Company Information
  69. 4.12.2 Calimmune Inc Business Overview
  70. 4.12.3 Calimmune Inc RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio
  72. 4.12.5 Calimmune Inc Recent Developments
  73. 4.13 Benitec Biopharma
  74. 4.13.1 Benitec Biopharma Company Information
  75. 4.13.2 Benitec Biopharma Business Overview
  76. 4.13.3 Benitec Biopharma RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio
  78. 4.13.5 Benitec Biopharma Recent Developments
  79. 4.14 Arrowhead Pharmaceuticals
  80. 4.14.1 Arrowhead Pharmaceuticals Company Information
  81. 4.14.2 Arrowhead Pharmaceuticals Business Overview
  82. 4.14.3 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
  84. 4.14.5 Arrowhead Pharmaceuticals Recent Developments
  85. 4.15 Alnylam Pharmaceuticals
  86. 4.15.1 Alnylam Pharmaceuticals Company Information
  87. 4.15.2 Alnylam Pharmaceuticals Business Overview
  88. 4.15.3 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
  90. 4.15.5 Alnylam Pharmaceuticals Recent Developments
  91. 4.16 Abbott Laboratories
  92. 4.16.1 Abbott Laboratories Company Information
  93. 4.16.2 Abbott Laboratories Business Overview
  94. 4.16.3 Abbott Laboratories RNA-based Biopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio
  96. 4.16.5 Abbott Laboratories Recent Developments
5 Global RNA-based Biopharmaceuticals Market Scenario by Region
  1. 5.1 Global RNA-based Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global RNA-based Biopharmaceuticals Sales by Region: 2021-2032
  3. 5.2.1 Global RNA-based Biopharmaceuticals Sales by Region: 2021-2026
  4. 5.2.2 Global RNA-based Biopharmaceuticals Sales by Region: 2027-2032
  5. 5.3 Global RNA-based Biopharmaceuticals Revenue by Region: 2021-2032
  6. 5.3.1 Global RNA-based Biopharmaceuticals Revenue by Region: 2021-2026
  7. 5.3.2 Global RNA-based Biopharmaceuticals Revenue by Region: 2027-2032
  8. 5.4 North America RNA-based Biopharmaceuticals Market Facts & Figures by Country
  9. 5.4.1 North America RNA-based Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  11. 5.4.3 North America RNA-based Biopharmaceuticals Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe RNA-based Biopharmaceuticals Market Facts & Figures by Country
  16. 5.5.1 Europe RNA-based Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  18. 5.5.3 Europe RNA-based Biopharmaceuticals Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific RNA-based Biopharmaceuticals Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific RNA-based Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific RNA-based Biopharmaceuticals Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America RNA-based Biopharmaceuticals Market Facts & Figures by Country
  41. 5.7.1 South America RNA-based Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  43. 5.7.3 South America RNA-based Biopharmaceuticals Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa RNA-based Biopharmaceuticals Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa RNA-based Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa RNA-based Biopharmaceuticals Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global RNA-based Biopharmaceuticals Sales by Type (2021-2032)
  2. 6.1.1 Global RNA-based Biopharmaceuticals Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global RNA-based Biopharmaceuticals Sales Market Share by Type (2021-2032)
  4. 6.2 Global RNA-based Biopharmaceuticals Revenue by Type (2021-2032)
  5. 6.2.1 Global RNA-based Biopharmaceuticals Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global RNA-based Biopharmaceuticals Revenue Market Share by Type (2021-2032)
  7. 6.3 Global RNA-based Biopharmaceuticals Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global RNA-based Biopharmaceuticals Sales by Application (2021-2032)
  2. 7.1.1 Global RNA-based Biopharmaceuticals Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global RNA-based Biopharmaceuticals Sales Market Share by Application (2021-2032)
  4. 7.2 Global RNA-based Biopharmaceuticals Revenue by Application (2021-2032)
  5. 7.2.1 Global RNA-based Biopharmaceuticals Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global RNA-based Biopharmaceuticals Revenue Market Share by Application (2021-2032)
  7. 7.3 Global RNA-based Biopharmaceuticals Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 RNA-based Biopharmaceuticals Value Chain Analysis
  2. 8.1.1 RNA-based Biopharmaceuticals Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 RNA-based Biopharmaceuticals Production Mode & Process
  5. 8.2 RNA-based Biopharmaceuticals Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 RNA-based Biopharmaceuticals Distributors
  8. 8.2.3 RNA-based Biopharmaceuticals Customers
9 Global RNA-based Biopharmaceuticals Analyzing Market Dynamics
  1. 9.1 RNA-based Biopharmaceuticals Industry Trends
  2. 9.2 RNA-based Biopharmaceuticals Industry Drivers
  3. 9.3 RNA-based Biopharmaceuticals Industry Opportunities and Challenges
  4. 9.4 RNA-based Biopharmaceuticals Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst